(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
09 June 2022 (09.06.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/119979 A1

(51) International Patent Classification:
A61K 38/46 (2006.01) *A61P 21/00* (2006.01)

(21) International Application Number:
PCT/US2021/061490

(22) International Filing Date:
01 December 2021 (01.12.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/119,977 01 December 2020 (01.12.2020) US
63/130,092 23 December 2020 (23.12.2020) US
63/278,746 12 November 2021 (12.11.2021) US

(71) Applicant: **LOCANABIO, INC.** [US/US]; 3545 John Hopkins Court, Suite 200, San Diego, California 92121 (US).

(72) Inventors: **NELLES, David A.**; c/o Locanabio, Inc., 3545 John Hopkins Court, Suite 200, San Diego, California 92121 (US). **BATRA, Ranjan**; c/o Locanabio, Inc., 3545 John Hopkins Court, Suite 200, San Diego, California 92121 (US). **ROTH, Daniela**; c/o Locanabio, Inc., 3545 John Hopkins Court, Suite 200, San Diego, California 92121 (US). **ZISOULIS, Dimitrios**; c/o Locanabio, Inc., 3545 John Hopkins Court, Suite 200, San Diego, California 92121 (US). **TA, Angeline**; c/o Locanabio, Inc., 3545 John Hopkins Court, Suite 200, San Diego, California 92121 (US).

(74) Agent: **ELRIFI, Ivor** et al.; Cooley LLP, 1299 Pennsylvania Ave., Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: RNA-TARGETING COMPOSITIONS AND METHODS FOR TREATING MYOTONIC DYSTROPHY TYPE 1




FIG. 4C

(57) Abstract: Disclosed are RNA-targeting gene therapy compositions and methods for destroying or blocking toxic target CUG repeat RNA and treating DM1.

WO 2022/119979 A1